Clinical Trials Logo

Diffuse Glioma clinical trials

View clinical trials related to Diffuse Glioma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06016452 Recruiting - Clinical trials for Glioblastoma Multiforme

A Study of Chlorophyllin for the Management of Brain Radio-necrosis in Patients With Diffuse Glioma

CHROME
Start date: November 13, 2023
Phase: Phase 2
Study type: Interventional

Diffuse gliomas are common tumors involving the brain. They are usually treated by surgery followed by radiation and chemotherapy. Radiotherapy is used for the treatment of brain tumors which causes damage to the tumor cells. However, radiotherapy can also affect the surrounding healthy cells in the brain, causing inflammation and swelling in the region, which is known as radio necrosis (RN). This is considered a late side effect of radiation and is seen in 10-25% of patients treated with radiation for brain tumors. Sometimes, radionecrosis can be detected on routine imaging during follow-up without new symptoms (asymptomaticRN). At the same time, in some patients, it can give rise to new symptoms like headaches, weakness, seizures,etc (symptomatic RN). The standard treatment of RN includes steroid medicines called dexamethasone, which is helpful in a proportion of patients. This is a prospective phase 2 study. This study is being conducted to investigate the ability of the drug Chlorophyllin in the treatment of radionecrosis. Chlorophyllin is a water-soluble compound obtained from the green plant pigment called chlorophyll. It has been shown to have anti-cancer, anti-bacterial, anti-viral, anti-inflammatory, and antioxidant properties. It is also used as an oral formulation and is an over-the-counter drug in various countries, and also as a food colouring agent. This is the first time chlorophyllin will be used in the setting of brain radionecrosis. Our primary aim of the study is to assess whether CHL will improve the clinical-radiological response rates. This study will be conducted on a population of 118 patients for a duration of 3 months. The total study duration is 2 years. The study is funded by Bhabha Atomic Research Centre (BARC).

NCT ID: NCT05717153 Recruiting - Malignant Glioma Clinical Trials

Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma

Start date: October 1, 2023
Phase: Early Phase 1
Study type: Interventional

This early phase I trial studies brain tumor (glioma) metabolism in response to eflornithine (DFMO) and polyamine transport inhibitor AMXT-1501 dicaprate (AMXT 1501) in patients with diffused or high grade glioma. Brain tumors use and produce certain molecules to survive and grow. DFMO is an irreversible inhibitor of ornithine decarboxylase, the enzyme catalyzing polyamine synthesis. AMXT 1501 is a polyamine transport inhibitor which prevents uptake of polyamines from the extracellular environment. This trial is being done to analyze how DFMO and AMXT 1501 affect brain tumor metabolism based on the molecules in the tumor's fluid.

NCT ID: NCT05553041 Recruiting - Glioma Clinical Trials

18F-Fluciclovine PET-MRI in High-grade Glioma

Start date: August 7, 2023
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to see if 18F-fluciclovine (Axumin®) PET imaging is useful and safe in the management of children with High Grade Gliomas. Investigators seek to determine if this imaging will help doctors tell the difference between tumor growth (progression) and other tumor changes that can occur after treatment.

NCT ID: NCT04910022 Recruiting - Glioblastoma Clinical Trials

Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma

Start date: December 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Multicenter, open-label, single-arm Phase 1/2 study on the safety and efficacy of the combination of NMS-03305293 and temozolomide (TMZ) in adult patients with diffuse gliomas (Phase 1) and isocitrate dehydrogenase (IDH) wild type glioblastoma (Phase 2) at first relapse.

NCT ID: NCT04047264 Recruiting - Glioblastoma Clinical Trials

Feasibility of Intraoperative Microdialysis During Neurosurgery for Central Nervous System Malignancies

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

This clinical trial evaluates the use of microdialysis catheters during surgery to collect biomarkers, and studies the feasibility of intraoperative microdialysis during neurosurgery for central nervous system malignancies. A biomarker is a measurable indicator of the severity or presence of disease state. Information collected in this study may help doctors to develop new strategies to better diagnose, monitor, and treat brain tumors.